Key result
Treating pre-implanted bovine embryos with the AGTR2 antagonist PD123319 significantly increased the proportion of hatched embryos compared with the control (P<0.05).
The pre-implanted bovine embryo expresses AGTR1 and AGTR2, and blockade of AGTR2 increases embryo hatching, suggesting maternal Ang II influences early embryonic development.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Ang II in bovine embryo development; leaves open any role in human assisted reproduction.
The renin-angiotensin system (RAS), mainly associated with the regulation of blood pressure, has been recently investigated in female reproductive organs and the developing foetus. Angiotensin II (Ang II) influences oviductal gamete movements and foetal development, but there is no information about RAS in the early embryo. The aim of this study was to determine whether RAS components are present in the pre-implantation embryo, to determine how early they are expressed and to investigate their putative role at this stage of development. Bovine embryos produced in vitro were used for analysis of RAS transcripts (RT-PCR) and localisation of the receptors AGTR1 and AGTR2 (immunofluorescent labelling). We also investigated the effects of Ang II, Olmesartan (AGTR1 antagonist) and PD123319 (AGTR2 antagonist) on oocyte cleavage, embryo expansion and hatching. Pre-implanted embryos possessed AGTR1 and AGTR2 but not the other RAS components. Both receptors were present in the trophectoderm and in the inner cell mass of the blastocyst. AGTR1 was mainly localised in granular-like structures in the cytoplasm, suggesting its internalisation into clathrin-coated vesicles, and AGTR2 was found mainly in the nuclear membrane and in the mitotic spindle of dividing trophoblastic cells. Treating embryos with PD123319 increased the proportion of hatched embryos compared with the control. These results, the first on RAS in the early embryo, suggest that the pre-implanted embryo responds to Ang II from the mother rather than from the embryo itself. This may be a route by which the maternal RAS influences blastocyst hatching and early embryonic development.
No takes yet. Share an insight, caveat, or question.
Pijacka et al. (2012) studied Pre-implantation embryo development. PD123319 (AGTR2 antagonist) vs. Control was evaluated on Proportion of hatched embryos (p=<0.05). Treating pre-implanted bovine embryos with the AGTR2 antagonist PD123319 significantly increased the proportion of hatched embryos compared with the control (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: